NEW in the MDx Product Portfolio of BÜHLMANN: MammaTyper® & RNXtract® from BioNTech

We are pleased to announce that with the new MammaTyper® Test from BioNTech, we could expand our MDx portfolio in the field of breast cancer biomarker detection and quantification with an innovative Genexpression Test, which reliably quantifies the four recommended genes according to the St. Gallen guidelines. For the extraction and purification of total RNA from FFPE samples, BioNTech developed additionally the RNXtract® Kit. For more information click here: